Agenda
August 1-2 | Hilton Motif Seattle + Virtually
Registered for the conference? View it here
Tuesday, August 1
(All times are in PT)
Breakfast Reception (in-person attendees)
7 - 8 a.m.
Welcome to the Spotlight on Immuno-Oncology
8 - 8:10 a.m.
Hans-Peter Kiem, MD, PhD
Fred Hutchinson Cancer Center
B-Cell Malignancies and Beyond
8:10 - 8:35 a.m.
Anna Truppel-Hartmann, MD
2seventy bio
Data from Phase 3 Clinical Trial for Multiple Myeloma
8:35 - 9 a.m.
Michael Jensen, MD
Seattle Children's Research Institute
Manufacturing Process Modulates CAR T Cell Efficacy and Fitness in Pediatric Subjects
9 - 9:25 a.m.
Carl June, MD
University of Pennsylvania
CAR T Cell Clinical Trials
9:25 - 9:50 a.m.
Rayne Rouce, MD
Baylor College of Medicine
CAR T for T-Cell Malignancies
9:50 - 10:05 a.m.
Biao Zheng, MD
BRL Medicine Inc.
High Safety and Efficacy of CRISPR-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells (BRL-201) in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma: First-in-Human Phase I Study
Novel CAR Designs and Approaches
10:05 - 10:15 a.m.
Break
10:15 - 10:40 a.m.
Robbie Majzner, MD
Stanford University
Novel CAR Designs
10:40 - 11:05 a.m.
Michel Sadelain, MD, PhD
Memorial Sloan Kettering Cancer Center
AG Sensitivity and T Cell Persistence
11:05 - 11:30 a.m.
Yvonne Chen, PhD
UCLA
Engineering Next-Generation CAR-T Cells for Cancer Immunotherapy
11:30 - 11:55 a.m.
Jardin Leleux, PhD
2seventy bio
RESET: A novel drug-regulated, TCR-coupled antigen receptor architecture
11:55 a.m. - 12:10 p.m.
Maik Luu, PhD
University Hospital Wurzburg
Microbial Metabolites Guide the Engineering and Epigenetic-Metabolic Reprogramming of CAR T Cells for the Treatment of Solid Tumors
12:10 - 1 p.m.
Lunch
TCR-Based Cancer Immunotherapy
1 - 1:25 p.m.
Chiara Bonini, MD
Vita-Salute San Raffaele University
TCR and Inhibitory Receptor Genome Editing
1:25 - 1:50 p.m.
Aude Chapuis, MD
Fred Hutchinson Cancer Research Center
All-hands on deck: Can we overcome the challenges associated with T cell receptor-based therapies?
1:50 - 2:15 p.m.
Chris Klebanoff, MD
Memorial Sloan Kettering Cancer Center
Immunogenicity and Therapeutic Targeting of Recurrently Mutated “Public” Neoantigens Using TCR Gene Therapy
2:15 - 2:40 p.m.
Dirk Busch, MD
Technical University of Munich
Advanced TCR engineering for polyclonal repertoire analysis and adoptive T cell therapy
2:40 - 2:55 p.m.
Elise Wilcox, PhD
Fred Hutchinson Cancer Center
Identification of Peptides Derived from Alternative Splicing for TCR-T Cell Therapies and Cancer Vaccines
Direct In Vivo Delivery
2:55 - 3:05 p.m.
Break
3:05 - 3:30 p.m.
Saar Gill, MBBS, PhD, FRACP
University of Pennsylvania
Direct in vivo transduction of CAR T cells
3:30 - 3:55 p.m.
Ed Rebar, PhD
Sana Biotechnology
In Vivo Engineering for Cancer Immunotherapy
3:55 - 4:20 p.m.
Frederic Thalheimer, PhD
Paul-Ehlrich-Institut
T Cell-Specific in vivo CAR-Delivery
4:20 - 4:45 p.m.
Andrew Scharenberg, MD
Umoja
Direct In Vivo Delivery
4:45 - 5 p.m.
Philip Johnson, MD
Interius Bio
Targeted in Vivo Generation of CAR T and NK Cells Utilizing an Engineered lEntiviral Vector Platform
5 - 6:30 p.m.
Poster viewing & reception
Wednesday, August 2
Genome and Epigenome Editing for Cancer Immunotherapy
8 - 8:25 a.m.
Pietro Genovese, PhD
Harvard Medical School
Epitope Editing of Hematopoietic Stem Cells to Enable Adoptive Immunotherapies for Acute Myeloid Leukemia
8:25 - 8:50 a.m.
Justin Eyquem, PhD
UCSF
Bridging Synthetic Immunology and Genome Editing to advance T Cell Therapies
8:50 - 9:15 a.m.
Jamie Schafer, PhD
Chroma Medicine
Using Epigenetic Editing to Engineer CAR T Cells
9:15 - 9:40 a.m.
Kole Roybal, PhD
UCSF
Towards the Development of Synthetic Immunity to Cancer
9:40 - 9:55 a.m.
Xiaomeng Hu
Sana Biotechnology
CD47 Enhances CAR T Survival in NSG Recipients and Allogeneic Mice
Beyond T Cells
9:55 - 10:05 a.m.
Break
10:05 - 10:30 a.m.
Paula Cannon, PhD
University of Southern California
Engineering B cells to express fully customizable antibodies
10:30 - 10:55 a.m.
Bob Valamehr, PhD
Fate Therapeutics, Inc.
iPSC-derived CAR T cells Uniformly Carrying Multiple Synthetic Modalities for the Off-the-Shelf Treatment of Cancer
10:55 - 11:20 a.m.
Michael Hudecek, MD
University Hospital Wurzburg
Minicircles & Transposon for T Cell Production
11:20 - 11:45 a.m.
Catherine Bollard, MD
The George Washington University
Native T-Cells for Adoptive Cell Therapy
11:45 a.m. - 12: 00 p.m.
Joshua Krueger
University of Minnesota
CD70 Knockout Provides Increased NK Cell Proliferation In Vivo